Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | BCL6 | P41182 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934273 | 0.87 | KMT2A (0.91) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL22866360 | 0.84 | KMT2A (0.97) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL16199054 | 0.84 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL10008381 | 0.84 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL29200245 | 0.84 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL9977770 | 0.84 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL17518644 | 0.84 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL2142331 | 0.84 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL2126173 | 0.84 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL2142335 | 0.84 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117887-B2 | Aryl substituted pyrimidines for use in influenza virus infection | Janssen Sciences Ireland Unlimited Company (IE) | 2021-09-14 | — | — | US | disclosed |
| US-20200231577-A1 | ARYL SUBSTITUTED PYRIMIDINES FOR USE INFLUENZA VIRUS INFECTION | Janssen Sciences Ireland Unlimited Company (IE) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117887-B2 | Aryl substituted pyrimidines for use in influenza virus infection | HPRT1, TYMP, PNP | KMT2A 1488/4885AXL 489/4885ALDH1A1 119/4885 |
| US-20200231577-A1 | ARYL SUBSTITUTED PYRIMIDINES FOR USE INFLUENZA VIRUS INFECTION | HPRT1, TYMP, UMPS | KMT2A 1500/4885AXL 436/4885ALDH1A1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.